Eravacycline for the treatment of complicated intra‐abdominal infections

Abstract Eravacycline is a novel fluorocycline antibiotic in the tetracycline class, with activities against multidrugresistant organisms, extended‐spectrum β‐lactamase‐producing (ESBL) bacteria, and carbapenem‐resistant Enterobacteriaceae . The approval of eravacycline by the U.S. Food and Drug Administration for the treatment of complicated intra‐abdominal infection (cIAIs) was based on the success of two‐Phase III clinical trials: IGNITE 1 and IGNITE 4. Two other Phase III trials, IGNITE 2 and IGNITE 3, have been conducted to assess efficacy and safety of eravacycline vs levofloxacin and ertapenem, respectively, for the treatment of complicated urinary tract infection, however, did not prove eravacycline's non‐inferiority. Therefore, eravacycline is approved for the treatment of cIAIs caused by gram‐positive organisms, gram‐negative organisms, and anaerobic pathogens in hospitalized patients aged 18 or older. Eravacycline has become a valuable medication to clinicians due to its unique coverage. Eravacycline is a great alternative in replacing carbapenems for patients with beta‐lactam allergy due to its ESBL coverage. In addition, eravacycline covers atypical organisms and Methicillin‐resistant Staphylococcus aureus , which carbapenems cannot. This article is a review of eravacycline's pharmacology, efficacy, safety profile, and potential clinical application.